Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

BACKGROUND: Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised of a monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassman, Andrew B, Pugh, Stephanie L, Wang, Tony J C, Aldape, Kenneth, Gan, Hui K, Preusser, Matthias, Vogelbaum, Michael A, Sulman, Erik P, Won, Minhee, Zhang, Peixin, Moazami, Golnaz, Macsai, Marian S, Gilbert, Mark R, Bain, Earle E, Blot, Vincent, Ansell, Peter J, Samanta, Suvajit, Kundu, Madan G, Armstrong, Terri S, Wefel, Jeffrey S, Seidel, Clemens, de Vos, Filip Y, Hsu, Sigmund, Cardona, Andrés F, Lombardi, Giuseppe, Bentsion, Dmitry, Peterson, Richard A, Gedye, Craig, Bourg, Véronique, Wick, Antje, Curran, Walter J, Mehta, Minesh P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925712/
https://www.ncbi.nlm.nih.gov/pubmed/35849035
http://dx.doi.org/10.1093/neuonc/noac173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925712/
https://www.ncbi.nlm.nih.gov/pubmed/35849035
http://dx.doi.org/10.1093/neuonc/noac173

Ejemplares similares